 

 

 

 

 

 

 

 

 

 

 

 

 

from FV of 10 to FV of
2 Each

November | 9,000 - | Conversion of CCPS to

22, 2021 Equity

Shareholders with Special Rights
1. ] Lavender Rose Investment | February 5, | 108,221 48,155.29 | Purchase
Ltd* 2021

February 5, | 12,114 Purchase

2021 47,385.19

July 9, 2021 | 601,675 - Split of Equity Shares
from EV of 10 to FV of
2 Each

November 24,067,000 > Conversion of CCPS to

22, 2021 Equity

November 2,804,480 277.38 Conversion of CCPS to

22, 2021 Equity"

 

 

 

“Entitled to nominate Directors on the Board of Directors of the Company.
"Price has been calculated taking in to consideration the price at which the underlying preference were acquired
AAs certified by GPHK & ASSOCIATES, Chartered Accountants, by way of certificate dated November 27, 2021

 

Weighted average
price at which the
specified securities
were acquired by
our Promoters and
Selling
Shareholders, in
the last one year

The weighted average price at which the specified securities were acquired by our Promoters, Promoter Group and
Selling Shareholders, in the last one year preceding the date of this Prospectus is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name of the Promoter Number of Equity Shares’ Weighted average price of
acquisition per Equity Share*®
(in?)
Lone Furrow Investments Private 17,233,240 174.08
Limited
Agilemed Investments Private Limited 15,649,495 175.72
Madhukar Gangadi 15,244,570 37.65
Selling Shareholders
PI Opportunities Fund — I 24,554,720 92.06
S. S. Pharma 18,30,475 NA.
Shore Pharma LLC 547,095 NA.
Natco Pharma Limited 446,315 NA.
Time Cap Pharma Labs Private Limited 445,705 NA.
‘A. Raghava Reddy 265,640 NA.
Ms. K Prakurthi 105,040 NA.
Sangeeta Raju 79,895, NA.
Navdeep Patyal 38,325, NA.
R. Venkat Reddy 29,605 NA.
TK Kurien 25,145, NA.
Nithya Venkataramani 22,915 NA.
Atul Gupta 22,915 NA.
Rahul Garg 22,915 NA.
Manoj Jaiswal 22,915 NA.
Kollengode Ramanathan 9,125 NA.
Lakshminarayana
Bijou Kurien 9,125 NA.

 

 

As of the date of filing this Prospectus

*As certified by GPHK & ASSOCIATES, Chartered Accountants, by way of certificate dated November 27, 2021
@ Alll the above Equity Shareholders have received bonus shares in the ratio of 1:1.25 on January 22, 2021 and hence the weighted

average price for such issuance is not applicable.

 

Average cost of
acquisition of
Equity Shares of
our Promoters and
the Selling
Shareholder

 

 

The average cost of acquisition of our Promoters and the Selling Shareholders is as follows:

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

 

 

 

20

 

Name Number of Equity Shares | Average cost of acquisition per
Equity Share* (in 2)

Promoters

Lone Furrow Investments Private Limited 17,233,240 174.08
Agilemed Investments Private Limited 15,649,495 175.72
Madhukar Gangadi 15,350,400 0.55
Selling Shareholders

PI Opportunities Fund — I 24,661,385, 158.02
S. S. Pharma 1,850,535 166.43
Shore Pharma LLC 553,090 166.41
Natco Pharma Limited 451,205 166.39
Time Cap Pharma Labs Private Limited 166.45
A. Raghava Reddy 94,41

 
